Investigation of biological and clinical predictor of antidepressant response for personalized medicine in depression ; a randomized controlled trial

INTERVENTION: Depressive patients are randomly assigned to either mirtazapine or SSRIs. Non‐responders after 4‐week treatment are randomly assigned to either maintain the same treatment or augmentation. Augmentation therapy are added to the subject who does not remit after 8‐week treatment. CONDITION: Major depression PRIMARY OUTCOME: Improvement of depressive symptom assessed by HAM‐D SECONDARY OUTCOME: Adverse effect assessed by UKU; QIDS; NEO personality inventory ; Social‐cognitive function INCLUSION CRITERIA: Drug naive patient (between 18 and 75 years old) with depression defined by DSN‐IV whose HAM‐D score are at least 14 .